Loading stock dataβ¦
$79.19-1.26 (-1.57%)
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $79.19 with a market capitalization of $7.8B. Wall Street consensus targets $119.93 (15 analysts), implying a +51.5% move over the next 12 months. The stock is currently 28% below its 52-week high of $110.17, remaining 13.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$81.64Mβ | -$75.64Mβ | -$57.17Mβ | -$56.89Mβ | -$51.94M |
| Net Income | -$36.20Mβ | -$69.00Mβ | -$62.53Mβ | -$11.18Mβ | -$36.72M |
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...